Theriva Biologics (FRA:SFY0) Cyclically Adjusted Book per Share: €-124.83 (As of Mar. 2026)


FRA:SFY0 Theriva Biologics Inc FRA:SFY0
24 GF Score
Price €2.42
! 3 Warning Signs
View Full Analysis

What is Theriva Biologics Cyclically Adjusted Book per Share?

Theriva Biologics FRA:SFY0 24 Cyclically Adjusted Book per Share is €-124.83 as of Mar. 2026. GuruFocus rates FRA:SFY0 with a GF Score™ of 24/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Theriva Biologics's adjusted book value per share for the three months ended in Mar. 2026 was €0.290. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €-124.83 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Theriva Biologics's average Cyclically Adjusted Book Growth Rate was -110.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -70.80% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -55.70% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -35.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Theriva Biologics was 28.20% per year. The lowest was -70.80% per year. And the median was -16.55% per year.

As of today (2026-07-11), Theriva Biologics's current stock price is €2.42. Theriva Biologics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €-124.83. Theriva Biologics's Cyclically Adjusted PB Ratio of today is .


Theriva Biologics  (FRA:SFY0) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Theriva Biologics Cyclically Adjusted Book per Share Related Terms


Theriva Biologics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Theriva Biologics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theriva Biologics Cyclically Adjusted Book per Share Chart

Theriva Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 538.26 415.78 203.32 120.24 130.78

Theriva Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 209.26 857.32 397.20 130.78 -124.83

FRA:SFY0 vs OSRH, PBM, PHIO: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Theriva Biologics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theriva Biologics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's Cyclically Adjusted PB Ratio falls into.


FRA:SFY0
24GF Score
Theriva Biologics Inc FRA:SFY0
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theriva Biologics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Theriva Biologics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.29/330.2130*330.2130
=0.290

Current CPI (Mar. 2026) = 330.2130.

Theriva Biologics Quarterly Data

Book Value per Share CPI Adj_Book
201606 204.200 241.018 279.770
201609 -398.800 241.428 -545.458
201612 280.385 241.432 383.490
201703 184.769 243.801 250.258
201706 286.600 244.955 386.353
201709 -938.533 246.819 -1,255.640
201712 -84.267 246.524 -112.874
201803 -172.267 249.554 -227.946
201806 -370.200 251.989 -485.120
201809 -152.381 252.439 -199.328
201812 160.323 251.233 210.724
201903 112.652 254.202 146.337
201906 67.194 256.143 86.625
201909 1.463 256.759 1.882
201912 -39.493 256.974 -50.749
202003 -66.465 258.115 -85.030
202006 -87.733 257.797 -112.377
202009 -92.797 260.280 -117.730
202012 -50.897 260.474 -64.524
202103 126.633 264.877 157.869
202106 120.263 271.696 146.165
202109 118.057 274.310 142.116
202112 109.633 278.802 129.849
202203 97.427 287.504 111.900
202206 92.025 296.311 102.554
202209 88.279 296.808 98.215
202212 80.871 296.797 89.976
202303 73.873 301.836 80.818
202306 60.928 305.109 65.941
202309 56.535 307.789 60.654
202312 49.410 306.746 53.190
202403 42.096 312.332 44.506
202406 26.854 314.175 28.225
202409 8.481 315.301 8.882
202412 6.545 315.605 6.848
202503 5.153 319.799 5.321
202506 1.017 322.561 1.041
202509 0.557 324.800 0.566
202512 0.368 324.054 0.375
202603 0.290 330.213 0.290

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €-124.83 mean?
Theriva Biologics (FRA:SFY0) has a Cyclically Adjusted Book per Share of €-124.83 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Theriva Biologics and its competitors.
Is Theriva Biologics' Cyclically Adjusted Book per Share too high?
Theriva Biologics' current Cyclically Adjusted Book per Share is €-124.83. Overall, Theriva Biologics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Theriva Biologics' Cyclically Adjusted Book per Share compare to OSRH and PBM?
Theriva Biologics' Cyclically Adjusted Book per Share of €-124.83 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Theriva Biologics and its competitors. Theriva Biologics's current Cyclically Adjusted Book per Share is €-124.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theriva Biologics stock overvalued right now?
Theriva Biologics (FRA:SFY0) has a current Cyclically Adjusted Book per Share of €-124.83. The current Cyclically Adjusted Book per Share is €-124.83. Theriva Biologics' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Theriva Biologics (FRA:SFY0), the current Cyclically Adjusted Book per Share is €-124.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Theriva Biologics Business Description

Other Exchanges TOVX:USA
Address 9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
24GF Score

Get the complete analysis for FRA:SFY0

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.42
Price